Exocrine Pancreatic Insufficiency Market Size Share & Forecast 2023

Exocrine Pancreatic Insufficiency Market Size, Competitive Landscape and Market Forecast - 2029

<h2>Global Exocrine Pancreatic Insufficiency Market is segmented By Disease Management (Nutritional management, Lifestyle modifications approach, Others), By Treatment Type (Pancreatic Enzyme Replacement Therapy, Creon, Zenpep, Pancreaze, Ultra, Viokace, Others), By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global Exocrine Pancreatic Insufficiency Market is expected to grow at a high <a href="https://www.datamintelligence.com/download-sample/exocrine-pancreatic-insufficiency-market">CAGR of 6.5%</a>&nbsp;during the forecasting period (2022-2029).
</blockquote>

<h2>Why purchase the report?</h2>

<ul>
	<li>
	Visualize the composition of the Exocrine Pancreatic Insufficiency Market across&nbsp;each indication, regarding type and application highlighting the critical commercial assets and players.
	</li>
	<li>
	Identify business opportunities in the exocrine&nbsp;Pancreatic Insufficiency Market by analyzing trends and co-development deals.
	</li>
	<li>
	Excel data sheet with thousands of data points of the Exocrine Pancreatic Insufficiency Market levels 4/5 segmentation.
	</li>
	<li>
	PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
	</li>
	<li>
	Product mapping in excel for the essential Meningitis Vaccines Market of all major market players.
	</li>
</ul>

<h2>Who can benefit from this report?</h2>

<ul>
	<li>
	Raw Material Suppliers/ Buyers
	</li>
	<li>
	Product Suppliers/ Buyers
	</li>
	<li>
	Industry Investors/Investment Bankers
	</li>
	<li>
	<a href="https://www.datamintelligence.com/enquiry/exocrine-pancreatic-insufficiency-market">Education &amp; Research Institutes</a>
	</li>
	<li>
	Research Professionals
	</li>
	<li>
	Emerging Companies
	</li>
	<li>
	Manufacturers
	</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topic&rsquo;s</h3>

<a href="https://www.datamintelligence.com/research-report/creatine-health-care-products-market">Creatine Health Care Products Market</a>

<a href="https://www.datamintelligence.com/research-report/particle-therapy-system-market">Particle Therapy System Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market Methodology and Scope</h3>

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; Executive Summary</h3>

	<ol>
		<li>
		Market Snippet by Treatment Type
		</li>
		<li>
		Market Snippet by End User
		</li>
		<li>
		DataM CLO Scenario
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; Dynamics</h3>

	<ol>
		<li>
		Market Impacting Factors

		<ol>
			<li>
			Drivers
			</li>
			<li>
			Restraints
			</li>
			<li>
			Impact Analysis
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; Industry Analysis&nbsp;</h3>

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Key Companies to Watch
		</li>
		<li>
		Epidemiology
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; By Disease Management</h3>

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Management
			</li>
			<li>
			Market Attractiveness Index, By Disease Management
			</li>
		</ol>
		</li>
		<li>
		Nutritional management

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%)
			</li>
		</ol>
		</li>
		<li>
		Lifestyle modifications approach
		</li>
		<li>
		Others
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; By Treatment Type</h3>

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Attractiveness Index, By Treatment Type
			</li>
		</ol>
		</li>
		<li>
		Pancreatic Enzyme Replacement Therapy

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%)
			</li>
		</ol>
		</li>
		<li>
		Creon
		</li>
		<li>
		Zenpep
		</li>
		<li>
		Pancreas
		</li>
		<li>
		Ultresa
		</li>
		<li>
		Viokace
		</li>
		<li>
		Others
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; By End User</h3>

	<ol>
		<li>
		Introduction

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
			<li>
			Market Attractiveness Index, By End User
			</li>
		</ol>
		</li>
		<li>
		Hospitals and Clinics

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%)
			</li>
		</ol>
		</li>
		<li>
		Ambulatory Surgical Centers
		</li>
		<li>
		Others
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; By Region</h3>

	<ol>
		<li>
		Introduction&nbsp;

		<ol>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
			</li>
			<li>
			Market Attractiveness Index, By Region
			</li>
		</ol>
		</li>
		<li>
		North America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				The U.S.
				</li>
				<li>
				Canada
				</li>
				<li>
				Mexico
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Europe

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Germany
				</li>
				<li>
				The U.K.
				</li>
				<li>
				France
				</li>
				<li>
				Italy
				</li>
				<li>
				Spain
				</li>
				<li>
				Rest of Europe
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		South America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Brazil
				</li>
				<li>
				Argentina
				</li>
				<li>
				Rest of South America
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Asia-Pacific

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				China
				</li>
				<li>
				India
				</li>
				<li>
				Japan
				</li>
				<li>
				Australia
				</li>
				<li>
				Rest of Asia Pacific
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		The Middle East and Africa

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Market &ndash; Competitive Landscape</h3>

	<ol>
		<li>
		Competitive Scenario
		</li>
		<li>
		Competitor Exocrine Pancreatic Insufficiency Market Strategy Analysis
		</li>
		<li>
		Comparative Drug Portfolio Analysis
		</li>
		<li>
		Market Positioning/Share Analysis
		</li>
		<li>
		Mergers and Acquisitions Analysis
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Market &ndash; Company Profiles</h3>

	<ol>
		<li>
		Eli Lilly &amp; Co

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Drug Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		Cilian AG
		</li>
		<li>
		Axcan
		</li>
		<li>
		Nordmark Arzneimittel GmbH &amp; Co. KG
		</li>
		<li>
		Aptalis Pharma, Inc.
		</li>
		<li>
		Digestive Care, Inc
		</li>
		<li>
		VIVUS Inc
		</li>
		<li>
		Mayoly Spindler
		</li>
		<li>
		AbbVie Inc
		</li>
		<li>
		Janssen Global Services
		</li>
	</ol>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; Premium Insights</h3>
	</li>
	<li>
	<h3>Global Exocrine Pancreatic Insufficiency Market &ndash; DataM</h3>

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables&nbsp;

TABLE 01. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2019, 20223&amp; 2029, BY DISEASE MANAGEMENT, ($MILLION)

TABLE 02. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2019, 20223&amp; 2029, BY DIAGNOSTIC TESTS, ($MILLION)

TABLE 03. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE 2019, 20223&amp; 2029, BY THERAPEUTIC DRUGS, ($MILLION)

TABLE 04. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE 2019, 20223&amp; 2029, BY REGION, ($MILLION)

TABLE 05. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE 2019, 20223&amp; 2029 (%), BY DISEASE MANAGEMENT ($MILLION)

TABLE 06. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 07. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE 2019, 20223&amp; 2029 (%), BY DIAGNOSTIC TESTS ($MILLION)

TABLE 08. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

TABLE 09.&nbsp;&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE 2019, 20223&amp; 2029 (%), BY THERAPEUTIC DRUGS ($MILLION)

TABLE 10. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 11. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE 2019, 20223&amp; 2029 (%), BY REGION ($MILLION)

TABLE 12. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY REGION, 2018&ndash;2028 ($MILLION)

TABLE 13. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 14.&nbsp;&nbsp;NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION) &nbsp;

TABLE 15. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 16. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY COUNTRY, 2018&ndash;2028 ($MILLION)

TABLE 17. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 18.&nbsp;&nbsp; SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)&nbsp;

TABLE 19. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 20. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY COUNTRY, 2018&ndash;2028 ($MILLION)

TABLE 21. EUROPE EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 22. EUROPE EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

TABLE 23. EUROPE EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 24. EUROPE EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY COUNTRY, 2018&ndash;2028 ($MILLION)

TABLE 25. ASIA PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 26.&nbsp;&nbsp;ASIA PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION) &nbsp;

TABLE 27. ASIA PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 28. ASIA PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY COUNTRY, 2018&ndash;2028 ($MILLION)

TABLE 29. MIDDLE EAST &amp; AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

TABLE 30. MIDDLE EAST &amp; AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

TABLE 31. MIDDLE EAST &amp; AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

TABLE 32. ELI LILLY &amp; CO: OVERVIEW

TABLE 33. ELI LILLY &amp; CO: PRODUCTPORTFOLIO

TABLE 34. ELI LILLY &amp; CO: KEY DEVELOPMENTS

TABLE 35. CILIAN AG: OVERVIEW

TABLE 36. CILIAN AG: PRODUCTPORTFOLIO

TABLE 37. CILIAN AG: KEY DEVELOPMENTS

TABLE 38. AXCAN: OVERVIEW

TABLE 39. AXCAN: PRODUCTPORTFOLIO

TABLE 40. AXCAN: KEY DEVELOPMENTS

TABLE 41. NORDMARK ARZNEIMITTEL GMBH &amp; CO. KG: OVERVIEW

TABLE 42. NORDMARK ARZNEIMITTEL GMBH &amp; CO. KG: PRODUCTPORTFOLIO

TABLE 43. NORDMARK ARZNEIMITTEL GMBH &amp; CO. KG: KEY DEVELOPMENTS

TABLE 44. APTALIS PHARMA, INC.: OVERVIEW

TABLE 45. APTALIS PHARMA, INC.: PRODUCTPORTFOLIO

TABLE 46. APTALIS PHARMA, INC.: KEY DEVELOPMENTS

TABLE 47. DIGESTIVE CARE, INC: OVERVIEW

TABLE 48. DIGESTIVE CARE, INC: PRODUCTPORTFOLIO

TABLE 49. DIGESTIVE CARE, INC: KEY DEVELOPMENTS

TABLE 50. VIVUS INC: OVERVIEW

TABLE 51. VIVUS INC: PRODUCTPORTFOLIO

TABLE 52. VIVUS INC:&nbsp; KEY DEVELOPMENTS

TABLE 53. MAYOLY SPINDLER: OVERVIEW

TABLE 54. MAYOLY SPINDLER: PRODUCTPORTFOLIO

TABLE 55. MAYOLY SPINDLER: KEY DEVELOPMENTS

TABLE 56. ABBVIE INC: OVERVIEW

TABLE 57. ABBVIE INC: PRODUCTPORTFOLIO

TABLE 58. ABBVIE INC: KEY DEVELOPMENTS

TABLE 59. JANSSEN GLOBAL SERVICES: OVERVIEW

TABLE 60. JANSSEN GLOBAL SERVICES: PRODUCTPORTFOLIO

TABLE 61. JANSSEN GLOBAL SERVICES: KEY DEVELOPMENTS

&nbsp;

List of Figures

FIGURE 01. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE, 2018 &amp; 2028 (%), BY DISEASE MANAGEMENT

FIGURE 02. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE, 2018 &amp; 2028 (%), BY DIAGNOSTIC TESTS

FIGURE 03. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE, 2018 &amp; 2028 (%), BY THERAPEUTIC DRUGS

FIGURE 04. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE, 2018 &amp; 2028 (%), BY REGION

FIGURE 05. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018 - 2028 AND YEAR ON YEAR GROWTH

FIGURE 06. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET YEAR ON YEAR GROWTH 2018 TO 2028 (%), BY DISEASE MANAGEMENT

FIGURE 07. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY NUTRITIONAL MANAGEMENT, 2018&ndash;2028 ($MILLION)

FIGURE 08.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY PANCREATIC ENZYME REPLACEMENT THERAPY, 2018&ndash;2028 ($MILLION)

FIGURE 09.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY LIFESTYLE MODIFICATIONS APPROACH, 2018&ndash;2028 ($MILLION)

FIGURE 10.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY ANALGESICS, 2018&ndash;2028 ($MILLION)

FIGURE 11. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET YEAR ON YEAR GROWTH 2018 TO 2028 (%), BY DIAGNOSTIC TESTS

FIGURE 12.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY MAGNETIC RESONANCE IMAGING, 2018&ndash;2028 ($MILLION)

FIGURE 13.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY CT SCANNING, 2018&ndash;2028 ($MILLION)

FIGURE 13.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY ENDOSCOPIC ULTRA-SONOGRAPHY, 2018&ndash;2028 ($MILLION)

FIGURE 13.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY BLOOD TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 13.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY OTHER TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 14. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET YEAR ON YEAR GROWTH 2018 TO 2028 (%), BY THERAPEUTIC DRUGS

FIGURE 15. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY CREON, 2018&ndash;2028 ($MILLION)

FIGURE 16.&nbsp;&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY ZENPEP, 2018&ndash;2028 ($MILLION)

FIGURE 17.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY PANCREAZE, 2018&ndash;2028 ($MILLION)

FIGURE 17.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY ULTRESA, 2018&ndash;2028 ($MILLION)

FIGURE 17.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY VIOKACE, 2018&ndash;2028 ($MILLION)

FIGURE 17.&nbsp; GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, BY OTHERS, 2018&ndash;2028 ($MILLION)

FIGURE 18. GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY MARKET YEAR ON YEAR GROWTH 2018 TO 2028 (%), BY REGION

FIGURE 19. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018&ndash;2028 ($MILLION)

FIGURE 20.&nbsp;&nbsp; NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)&nbsp;

FIGURE 21.&nbsp;&nbsp; NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 22. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

FIGURE 23. NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2028 ($MILLION)

FIGURE 24. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018&ndash;2028 ($MILLION)

FIGURE 25.&nbsp;&nbsp; SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DISEASE MANAGEMENT, 2018-2028($MILLION) &nbsp;&nbsp;

FIGURE 26.&nbsp;&nbsp; SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DIAGNOSTIC TESTS, 2018-2028($MILLION)

FIGURE 27. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

FIGURE 28. SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2028 ($MILLION)

FIGURE 29. &nbsp;EUROPE EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018&ndash;2028 ($MILLION)

FIGURE 30.&nbsp; EUROPE RHEUMATOID ARTHRITIS MARKET SHARE (%), BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION) &nbsp;

FIGURE 31. EUROPE RHEUMATOID ARTHRITIS MARKET SHARE (%), BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 32. EUROPE RHEUMATOID ARTHRITIS MARKET SHARE (%), BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

FIGURE 33. EUROPE RHEUMATOID ARTHRITIS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2028 ($MILLION)

FIGURE 34. &nbsp;ASIA PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018&ndash;2028 ($MILLION)

FIGURE 35. ASIA PACIFIC RHEUMATOID ARTHRITIS MARKET SHARE (%), BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)

FIGURE 36. ASIA PACIFIC RHEUMATOID ARTHRITIS MARKET SHARE (%), BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 37. &nbsp;ASIA PACIFIC RHEUMATOID ARTHRITIS MARKET SHARE (%), BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

FIGURE 38. ASIA PACIFIC RHEUMATOID ARTHRITIS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2028 ($MILLION)

FIGURE 39.&nbsp; MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET VALUE, 2018&ndash;2028 ($MILLION)

FIGURE 40.&nbsp; MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DISEASE MANAGEMENT, 2018&ndash;2028 ($MILLION)&nbsp;

FIGURE 41.&nbsp; MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY DIAGNOSTIC TESTS, 2018&ndash;2028 ($MILLION)

FIGURE 42.&nbsp; MIDDLE EAST &amp; AFRICA EXOCRINE PANCREATIC INSUFFICIENCY MARKET SHARE (%), BY THERAPEUTIC DRUGS, 2018&ndash;2028 ($MILLION)

FIGURE 43. ELI LILLY &amp; CO: FINANCIALS

FIGURE 44. CILIAN AG: FINANCIALS

FIGURE 45. AXCAN: FINANCIALS

FIGURE 46.&nbsp; &nbsp;ABBVIE INC: FINANCIALS

FIGURE 47. APTALIS PHARMA, INC.: FINANCIALS

FIGURE 48. DIGESTIVE CARE, INC: FINANCIALS

FIGURE 49. &nbsp;VIVUS INC.: FINANCIALS

FIGURE 50. MAYOLY SPINDLER: FINANCIALS

FIGURE 51. NORDMARK ARZNEIMITTEL GMBH &amp; CO. KG: FINANCIALS

FIGURE 52. JANSSEN GLOBAL SERVICES: FINANCIALS